# DELIVER

Study · id `cardio:deliver` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A large trial in adults with heart failure and an ejection fraction above 40%, which covers mildly reduced and preserved values. About half were given dapagliflozin 10 mg once a day and half a placebo, on top of usual treatment. Over a median of 2.3 years, fewer people on dapagliflozin had worsening heart failure or died from cardiovascular causes. When cardiovascular death was counted on its own, the abstract reports a hazard ratio of 0.88 with a confidence interval that includes 1.

## Technical summary

AstraZeneca-sponsored, randomized, placebo-controlled phase 3 study (NCT03619213) of 6263 patients with heart failure and a left ventricular ejection fraction of more than 40%. Primary outcome: worsening heart failure or cardiovascular death, hazard ratio 0.82 (95% CI 0.73 to 0.92) over a median of 2.3 years, from the PubMed abstract. Worsening heart failure alone: hazard ratio 0.79 (95% CI 0.69 to 0.91). Cardiovascular death alone: hazard ratio 0.88 (95% CI 0.74 to 1.05). The registry condition and title say preserved ejection fraction, while the abstract title says mildly reduced or preserved. The full text was not read. Funding is stated in the abstract as AstraZeneca.

## Key facts

- Design: Randomized, parallel-group, double-blind, placebo-controlled phase 3 study of dapagliflozin 10 mg once daily added to usual therapy in people with an ejection fraction above 40%. The registry records masking as quadruple.
- Phase: Phase 3
- Enrolled: 6263 patients (randomized count; Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction, snapshot `cardio:pubmed-36027570-2026-10-14`, retrieved 2026-10-14)
- Started: 2018-08-27 (actual) (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure., snapshot `cardio:ctgov-nct03619213-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2022-03-27 (actual) (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure., snapshot `cardio:ctgov-nct03619213-2026-10-14`, retrieved 2026-10-14)
- Completion: 2022-03-27 (actual) (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure., snapshot `cardio:ctgov-nct03619213-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2023-07-11 (actual) (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure., snapshot `cardio:ctgov-nct03619213-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Belgium; Brazil; Bulgaria; Canada; China; Czechia; Hungary; Japan; Mexico; Netherlands; Peru; Poland; Romania; Russia; Saudi Arabia; Spain; Taiwan; Vietnam (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure., snapshot `cardio:ctgov-nct03619213-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct03619213-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Tests this medicine: Dapagliflozin (`cardio:dapagliflozin`)
- Studies people with this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Lead sponsor on the registry record: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: e1268e0727fac8f8c656b3f3627b30c70105a64a0c2c6be488235b785504e3c6
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14